FHA
VRTX icon

Flagship Harbor Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Flagship Harbor Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
1,644
+71
+5% +$33.1K 0.03% 381
2025
Q4 		$713K Sell
1,573
-17
-1% -$7.33K 0.03% 364
2025
Q3 		$623K Sell
1,590
-30
-2% -$12.5K 0.03% 438
2025
Q2 		$721K Buy
1,620
+85
+6% +$39.2K 0.03% 383
2025
Q1 		$744K Buy
1,535
+13
+0.9% +$6.06K 0.04% 343
2024
Q4 		$613K Hold
1,522
– – 0.03% 371
2024
Q3 		$708K Sell
1,522
-444
-23% -$213K 0.04% 339
2024
Q2 		$922K Buy
1,966
+58
+3% +$25.2K 0.06% 273
2024
Q1 		$798K Sell
1,908
-4
-0.2% -$1.69K 0.05% 280
2023
Q4 		$778K Buy
1,912
+341
+22% +$126K 0.06% 262
2023
Q3 		$546K Buy
1,571
+70
+5% +$24.5K 0.05% 307
2023
Q2 		$528K Buy
1,501
+100
+7% +$33.7K 0.04% 317
2023
Q1 		$441K Sell
1,401
-261
-16% -$78.3K 0.04% 378
2022
Q4 		$480K Sell
1,662
-62
-4% -$18.9K 0.05% 346
2022
Q3 		$499K Buy
1,724
+406
+31% +$117K 0.06% 312
2022
Q2 		$371K Buy
1,318
+14
+1% +$3.75K 0.04% 389
2022
Q1 		$340K Sell
1,304
-12
-0.9% -$2.85K 0.03% 446
2021
Q4 		$289K Buy
1,316
+214
+19% +$41.6K 0.03% 506
2021
Q3 		$222K Hold
1,102
– – 0.02% 576
2021
Q2 		$222K Buy
+1,102
New +$231K 0.02% 577
2020
Q4 		– Sell
-794
Closed -$216K – 1743
2020
Q3 		$216K Buy
794
+74
+10% +$20.4K 0.03% 449
2020
Q2 		$209K Buy
720
+148
+26% +$40.1K 0.03% 451
2020
Q1 		$136K Buy
572
+58
+11% +$13.3K 0.03% 473
2019
Q4 		$113K Hold
514
– – 0.02% 582
2019
Q3 		$87K Hold
514
– – 0.02% 624
2019
Q2 		$94K Buy
514
+16
+3% +$2.8K 0.02% 587
2019
Q1 		$91K Hold
498
– – 0.02% 586
2018
Q4 		$82K Sell
498
-228
-31% -$39.5K 0.02% 570
2018
Q3 		$139K Sell
726
-11
-1% -$1.96K 0.03% 505
2018
Q2 		$125K Buy
+737
New +$114K 0.03% 516

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Flagship Harbor Advisors's VRTX Position: Q1 2026 in Review

Flagship Harbor Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 4.5% in Q1 2026, buying an estimated $33.1K and bringing the position to 1,644 shares worth $734K. The position accounts for 0.03% of the portfolio, ranked #381.

Flagship Harbor Advisors first reported a position in VRTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $922K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Flagship Harbor Advisors held 1,644 shares of Vertex Pharmaceuticals worth $734K as of Q1 2026.
  • Flagship Harbor Advisors bought 71 Vertex Pharmaceuticals shares in Q1 2026, an estimated $33.1K.
  • Vertex Pharmaceuticals made up 0.03% of Flagship Harbor Advisors's portfolio in Q1 2026, its #381 holding.
  • Flagship Harbor Advisors first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Flagship Harbor Advisors's Vertex Pharmaceuticals position peaked at $922K in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.